Arabic Arabic English English French French German German

BioSyent to Present at the LD 500 Virtual Conference

MISSISSAUGA, Ontario, Aug. 24, 2020 (GLOBE NEWSWIRE) — BioSyent Inc.  (“BioSyent”, “the Company”, TSX Venture: RX) today announced that it will be presenting at the LD 500 investor conference on Thursday, September 3rd at 2:40 p.m. (ET).  Mr. René Goehrum, President and CEO of BioSyent, will be presenting to a live virtual audience.  Mr. Goehrum will also be available to meet with investors on a one-on-one basis during the conference on September 1st to 4th.  These one-on-one meetings can be requested by registered attendees through the online conference portal:

About BioSyent Inc.

Listed on the TSX Venture Exchange under the trading symbol “RX”, BioSyent is a profitable growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical and other healthcare products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients.  BioSyent supports the healthcare professionals that treat these patients by marketing its products through its community, specialty/hospital and international business units.  

As of the date of this press release, the Company has 12,808,170 common shares outstanding.

For a direct market quote for the TSX Venture Exchange and other Company financial information please visit

For further information please contact:

Mr. René C. Goehrum

President and CEO

BioSyent Inc.


Phone: 905-206-0013


This press release may contain information or statements that are forward-looking.  The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be materially different from the forward-looking information or statements.  Potential risks may include, but are not limited to, those associated with clinical trials, product development, future revenue, operations, profitability and obtaining regulatory approvals. 

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.


Primary Logo

Read More

Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

US FDA Awards Orphan Drug Designation (ODD) To Paxalisib For Malignant Glioma, Including DIPG

Next Post

Canadian emergency department visits drop 25% in early weeks of COVID-19 pandemic

Related Posts